Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 920 results for "novartis"

Afinitor receives EU recommendation to treat rare lung cancer

BRIEF-Novartis says Afinitor gets nod in EU for some GI, lung ...

April 29 Novartis Ag * Novartis says afinitor recommended by chmp for european union approval to treat select gi and lung neuroendocrine tumors Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom) Our top ... Reuters UK, 1 day ago
Bidness Etc

FY2016 EPS Estimates for Novartis AG (NVS) Reduced by Analyst

Novartis AG (NYSE:NVS) Investment analysts at Jefferies Group reduced their FY2016 earnings estimates for shares of Novartis AG in a research report issued to clients and investors on Tuesday, according to Zacks Investment Research . Jefferies ...
 WKRB News14 hours ago Analysts See Increase of Novartis AG (ADR) (NVS) Earnings Per Share  Octafinance3 days ago Novartis AG (ADR) Under Pressure on Q1 Revenue Decline  Bidness Etc1 week ago

The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Novartis, Baxalta Incorporated and Shire

By Zacks Equity Research 35
 Yahoo! Finance1 day ago

BRIEF-Celgene says 2020 Revlimid forecast is conservative: conf call

April 28 Celgene Execs Say Otezla Continues To Grow At Similar Rate After Novartis' Cosentyx Launch - Conf Call * Celgene Execs Say Otezla Continues To Gain Market Share - Conf Call * Celgene Execs Say The Fundamentals For Revlimid And ...
 Reuters UK1 day ago
Trade Arabia

Novartis Puts US$14B Roche Stake Up For Sale

The Novartis stake amounts to 33 percent of Roche's voting shares. Novartis built up its one-third stake in Roche's voting stock between 2001 and 2003. April 28, 2016 By Denice Cabel Joe Jimenez Novartis Roche Novartis is discussing ...
 PharmaAsia2 days ago Novartis in Rumored Talks to Sell $14 Billion Roche Stake  Converter News3 days ago Novartis: Eyes on Roche stake sale  Business Line4 days ago Novartis discussing $14 billion stake sale with Roche, but not imminent: Sources  Economic Times5 days ago
Money Control

GlaxoSmithKline adjusted net dips by 96% in Q1 to £352 mn

GlaxoSmithKline (GSK), which completed Novartis transaction on March 2, 2015, has posted lower net profit of £352 million only during the first quarter ended March 2016 as against £8,038 million in the corresponding period of last year. This is ...
 PharmaBiz2 days ago Novartis first quarter core net falls amid Alcon, Entresto revival bid  Business Recorder5 days ago Novartis reports $11.6 billion in net sales in first quarter  Healio4 days ago Novartis overcomes eyecare, heart drug pain with older drugs  Money Control1 week ago

Analysts Recommendations: Most Rate Novartis a Buy

Novartis's 1Q16 Earnings Got a Neutral Response from Investors ( Continued from Prior Part ) Analysts estimates Novartis (NVS) experienced various changes through acquisitions and divestments over the last two years. Novartis missed analysts ...
 Yahoo! Finance UK and Ireland2 days ago Novartis's Pharmaceutical Revenue Reported Growth in 1Q16  Yahoo! Finance UK and Ireland3 days ago Novartis Reported Operational Growth in Its 1Q16 Earnings  Yahoo! 7 Finance4 days ago Revenue growth at GSK  MedNous1 day ago

New heart failure drug recommended by NICE

NICE has recommended new heart failure drug sacubitril valsartan (Entresto, Novartis), the first drug of its kind, as an option for some people with heart failure. The guidance recommends the £3 per day treatment for this life-threatening ...
 GM Journal1 day ago Novartis Heart Drug Gets Endorsed by NICE, But Not for Everyone  Bloomberg3 days ago NOVARTIS : NICE backs restricted use of heart drug Entresto  4 Traders2 days ago NICE gives green light to Novartis's heart drug Entresto  Pharmafile3 days ago

Biotech Forum Daily Digest: Sarepta Plunges On Ad Comm Decision, Novartis To Be Player In M&A? Spotlight On Exelixis

Trading Tuesday began with a couple major blow ups within Biotech Land. Sarepta Therapeutics (NASDAQ: SRPT ) , which we have covered extensively in the last week; collapsed after it Ad Comm panel refused to recommend its drug eteplirsen for Duchenne ...
 Seeking Alpha3 days ago
Money Control

Aurobindo Pharma gets USFDA nod for blood pressure drug

The drug is bio-equivalent and therapeutically equivalent to the reference listed product Exforge of Novartis Pharmaceuticals Corporation.
 Money Control4 days ago Aurobindo Pharma gets final USFDA nod for dementia drug  Economic Times1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis
Get updated on latest news & your favorite topics right in your inbox!
More     Less